MOR - モ―ニングスタ― (MorphoSys AG) モ―ニングスタ―

 MORのチャート


 MORの企業情報

symbol MOR
会社名 Morningstar Inc (モ―ニングスタ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    金融(Financials)
概要 事業概要 --   モ―ニングスタ―は、米国の投資リサ―チ会社。北米、ヨ―ロッパ、オ―ストラリア、アジアにおいて投資リサ―チ事業を展開。米国にて投資顧問、資産運用会社、退職金制度提供者・スポンサ―、個人投資家向けに商品およびサ―ビスを提供。またアジア、オ―ストラリア、カナダ、ヨ―ロッパ、中南米、南アフリカの投資家向けに設計され商品を提供する。   
本社所在地 22 West Washington Street Chicago IL 60602 USA
代表者氏名
代表者役職名
電話番号
設立年月日 30803
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 4920人
url www.morningstar.com
nasdaq_url https://www.nasdaq.com/symbol/mor
adr_tso 10205648
EBITDA EBITDA ー
終値(lastsale) 23.93
時価総額(marketcap) 244221156.64
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 MORのテクニカル分析


 MORのニュース

   The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs  2021/10/08 11:31:17 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS ) Bicycle Therapeutics plc (NASDAQ: BCYC ) (announced interim Phase 1 data for BT5528 and preliminary results from Phase 1 study of BT8009) Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX ) Cytokinetics, Incorporated (NASDAQ: CYTK ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) Legend Biotech Corporation (NASDAQ: LEGN ) Click here for accessing Benzinga''s FDA Calendar Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 7) Acutus Medical, Inc. (NASDAQ: AFIB ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Amgen Inc. (NASDAQ: AMGN ) ( announced neurodegenerative disease drug collaboration with Nuemora) Angion Biomedica Corp. (NASDAQ: ANGN ) Applied DNA Sciences, Inc. (NASDAQ: APDN ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Avenue Therapeutics, Inc.
   Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer  2021/09/20 12:30:00 Intrado Digital Media
LOS ANGELES, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Aadi) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Brendan Delaney to the role of Chief Operating Officer (COO). Brendan has had an established career in oncology-focused commercial leadership roles, launching multiple groundbreaking new products and building effective and cohesive commercial teams. Most recently Brendan was Chief Commercial Officer at Constellation Pharmaceuticals, which was acquired by MorphoSys AG for $1.4 billion prior to a commercial launch of pelabresib a first-in-class BETi inhibitor with blockbuster potential across multiple hematology indications. Prior to this, as Chief Commercial Officer at Immunomedics, Inc. Brendan led the launch of TRODELVY ® , the first TROP-2 directed antibody-drug conjugate for the treatment of triple-negative breast cancer which was acquired by Gilead Sciences, Inc.
   MorphoSys, SMA Solar und Fraport am besten (Peer Group Watch Deutsche Nebenwerte powered by Erste Group)  2021/09/17 08:19:00 Borse Social Network
   The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study  2021/09/16 11:48:49 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC ) Bicycle Therapeutics plc (NASDAQ: BCYC ) Bio-Techne Corporation (NASDAQ: TECH ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA ) IVERIC bio, Inc. (NASDAQ: ISEE ) Kezar Life Sciences, Inc. (NASDAQ: KZR ) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) Repligen Corporation (NASDAQ: RGEN ) Vera Therapeutics, Inc. (NASDAQ: VERA ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 15) 4D pharma plc (NASDAQ: LBPS ) (announced biomarker analyses from two studies of MRx0518 in solid tumor settings) Achilles Therapeutics plc (NASDAQ: ACHL ) Acutus Medical, Inc. (NASDAQ: AFIB ) Aditxt, Inc. (NASDAQ: ADTX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Ardelyx, Inc. (NASDAQ: ARDX ) AzurRx BioPharma, Inc. (NASDAQ: AZRX ) CVRx, Inc. (NASDAQ: CVRX ) Dermata Therapeutics, Inc.
   MorphoSys, Fraport, BB Biotech am schwächsten (Peer Group Watch Deutsche Nebenwerte powered by Erste Group)  2021/09/15 07:57:00 Borse Social Network
   MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2021 Results - Earnings Call Transcript  2021/07/31 17:09:04 Seeking Alpha
   MorphoSys AG (MOR) Q2 2021 Earnings Call Transcript  2021/07/31 13:00:40 The Motley Fool
MOR earnings call for the period ending June 30, 2021.
   MorphoSys AG deutsch  2021/07/30 14:02:46 Ad Hoc News
MorphoSys AG deutsch. MorphoSys AG, DE0006632003
   The Daily Biotech Pulse: Merck''s Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs  2021/07/29 12:15:52 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV ) Alkermes plc (NASDAQ: ALKS ) (reacted to second-quarter results) Arvinas, Inc. (NASDAQ: ARVN ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioNTech SE (NASDAQ: BNTX ) (reacted to COVID-19 vaccine sales revealed by Pfizer, Inc. in its quarterly results) Cassava Sciences, Inc. (NASDAQ: SAVA ) (saw an acceleration in momentum set in motion by Alzheimer''s data release) Edwards Lifesciences Corporation (NYSE: EW ) Globus Medical, Inc. (NYSE: GMED ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Repligen Corporation (NASDAQ: RGEN ) (reacted to second-quarter results) ResMed Inc. (NYSE: RMD ) West Pharmaceutical Services, Inc. (NYSE: WST ) Translate Bio, Inc. (NASDAQ: TBIO ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 28) 89bio, Inc. (NASDAQ: ETNB ) Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS ) Adicet Bio, Inc. (NASDAQ: ACET ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) Biodesix, Inc. (NASDAQ: BDSX ) Candel Therapeutics, Inc.
   MorphoSys Turns To Profit In Q2  2021/07/29 03:16:00 FinanzNachrichten
MARTINSRIED (dpa-AFX) - MorphoSys AG (MOR) reported that its net profit for the second-quarter was 20.9 million euros compared to a net loss of 53.1 million euros in the prior year.Operating loss
   Morphosys Aktie: MIT DIESEN WAHNSINNIGEN KURSEN rechnet am Montag niemand! Das ist der Grund!  2021/06/19 06:03:09 Wallstreet:Online
[Eilmeldung zur Morphosys Aktie] Achtung, es gibt heute, am 19. Juni 2021, aktuelle Neuigkeiten zur Morphosys Aktie, die sich stark auf die Kursentwicklung auswirken werden. Jetzt meine neueste Analyse lesen und sofort reagieren: Der Beitrag Morphosys Aktie: MIT DIESEN WAHNSINNIGEN KURSEN rechnet am Montag niemand! Das ist der Grund! erschien zuerst auf Felix Haupt.
   AUFREGENDER BÖRSENSCHLUSS: Morphosys Aktie steckt heftige Kurskapriolen ein! (Freitag)  2021/06/18 15:00:00 Wallstreet:Online
[Eilmeldung zur Morphosys Aktie] Achtung, es gibt heute, am 18. Juni 2021, aktuelle Neuigkeiten zur Morphosys Aktie, die sich stark auf die Kursentwicklung auswirken werden. Jetzt meine neueste Analyse lesen und sofort reagieren: Der Beitrag AUFREGENDER BÖRSENSCHLUSS: Morphosys Aktie steckt heftige Kurskapriolen ein! (Freitag) erschien zuerst auf Felix Haupt.
   Aktien - Lufthansa, MorphoSys, Nordex, TeamViewer, Zalando & Co.: Neuigkeiten von Shortsellern  2021/06/18 14:18:13 4investors
Wer Aktien leer verkauft, das sogenannte Shortselling, muss bestimmte Transparenzpflichten erfüllen. Geregelt sind diese in der
   MorphoSys: Risikoreiche Constellation-Übernahme angekündigt Aktienanalyse  2021/06/18 08:41:06 Investor SMS
Frankfurt (www.aktiencheck.de) - MorphoSys-Aktienanalyse von Analyst Tobias Gottschalt von Independent Research: Tobias Gottschalt, Analyst von Independent Research, streicht in einer aktuellen Aktienanalyse seine Kaufempfehlung für die Aktie des B
   Morphosys: Deutliche Kritik an den Akquisitionsplänen  2021/06/18 08:31:09 4investors
Morphosys will Constellation Pharmaceuticals übernehmen. Geboten werden 34,00 Dollar je Aktie, das entspricht einem Übernahmepreis von 1,7

 関連キーワード  (― 米国株 モ―ニングスタ― MOR MorphoSys AG)

 twitter  (公式ツイッターやCEOツイッターなど)